Ginger Treatment For Cancer-Related Nausea and Vomiting
Name of the Trial
Phase II Randomized Study of Ginger in Patients with Cancer and Chemotherapy-Induced Nausea and Vomiting (CCUM-0201). See the protocol summary at http://cancer.gov/clinicaltrials/CCUM-0201.
Dr. Suzanna Zick, University of Michigan Integrative Medicine.
Why Is This Trial Important?
Nausea and vomiting are among the most distressing and feared side effects of cancer and cancer treatment. Beyond being unpleasant, the nausea and vomiting associated with cancer and its treatment can lead to serious and life-threatening complications, such as nutritional depletion, metabolic imbalance, esophageal damage, expulsion of oral chemotherapy agents, and withdrawal from potentially curative treatment. Thus, effective treatment for nausea and vomiting is critical to the care of cancer patients.
In this trial, researchers are testing the ability of two different doses (lower vs. higher) of the herb ginger to treat delayed nausea and vomiting associated with chemotherapy. Ginger is believed to affect receptors in the digestive tract for the neurotransmitter serotonin. This action is similar to conventional antinausea drugs.
"Ginger has been shown to be effective in a number of clinical trials against nausea and vomiting associated with motion sickness, pregnancy, and postoperative recovery," said Dr. Zick. "With this trial, we hope to determine its efficacy and safety for chemotherapy-induced nausea and vomiting.
"We hope ginger will be effective for patients who continue to experience delayed nausea and vomiting despite treatment with other antinausea drugs," Dr. Zick added.
Who Can Join This Trial?
Researchers seek to enroll 180 cancer patients aged 18 or older who are undergoing chemotherapy and have experienced nausea or vomiting during or following a previous treatment cycle. See the full list of eligibility criteria at http://cancer.gov/clinicaltrials/CCUM-0201.
Where Is This Trial Taking Place?
The study is being conducted at sites in the United States through the Community Clinical Oncology Program (CCOP) and elsewhere. See the list of study sites at http://cancer.gov/clinicaltrials/CCUM-0201.
For more information, see the list of study contacts at http://cancer.gov/clinicaltrials/CCUM-0201 or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). This call is completely confidential.
An archive of "Featured Clinical Trial" columns is available at